| 1 | The future of cancer immunotherapy:microenvironmenttargeting combinations显示文摘Immunotherapy holds the potential to induce durable responses,but only a minority of patients currently respond.The etiologies of primary and secondary resistance to immunotherapy are multifaceted,deriving not only from tumor intrinsic faaors,but also from the complex interplay between cancer and its microenvironment.In addressing frontiers in clinical immunotherapy,we describe two categories of approaches to the design of novel drugs and combination therapies:the first involves direct modification of the tumor,while the second indirectly enhances immunogenicity through alteration of the microenvironment.By systematically addressing the factors that mediate resistance,we are able to identify mechanistically-driven novel approaches to improve immunotherapy outcomes. | Yonina R.Murciano-Goroff Allison Betof Warner Jedd D.Wolchok | 2020 | Cell Research2020，30，6： | 12 |
您所在的机构暂未开通此部分的功能，请联系管理员